Tong LX, Liu SX, Guo LH, Duan W, Chen BL, Wang HF, Liu LP, Shen W, Wang SY. Clinical effects of autologous dendritic cells combined with anti-virus therapy on chronic hepatitis B virus infection.
Shijie Huaren Xiaohua Zazhi 2007;
15:1232-1236. [DOI:
10.11569/wcjd.v15.i11.1232]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To evaluate the clinical effects of autologous HBsAg-loaded dendritic cells (DCs) combined with anti-viral treatment on patients with chronic hepatitis B virus (HBV) infection.
METHODS: A total of 41 chronic HBV infected subjects were treated with single interferon-α-2b for 6 mo before the trial, and the treatment was stopped for the irresponsive cases. Six months later, the irresponsive cases received the combined therapy of interferon-α-2b and autologous HBsAg-loaded DCs for another 6 mo (one course containing twice of re-transfusion). The changes of virology, serology and biochemistry indexes were observed one month after the end of treatment.
RESULTS: DCs were cultured in vitro. After proliferation for 6 d, DCs were incubated with HBsAg for 1 d to prepare the specific DCs vaccine. The levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were significant decreased after the combined therapy as compared with those before (t = 2.976, P < 0.01; t = 2.049, P < 0.05). The response rate of HBV DNA was 53.7%, and the decrease of HBV DNA copies was greater than or equal to 2log10. Neither the injection times of DCs nor the HBV-carrying time had a correlation with the virological responses (r = 0.048, P > 0.05; r = 0.137, P > 0.05).
CONCLUSION: Combined treatment of autologous DCs vaccine and interferon-α-2b has a favorable effect on patients with chronic HBV infection.
Collapse